News About: Pharm. Industry
When the pharmaceutical environment is unreliable, listed pharmaceutical companies focus on collecting cashable assets
It is pointed out that listed pharmaceutical companies are focusing on possessing cash in case of an emergency.
According to the YakupDotCom’s analysis result of cashable assets of 55 KOSDAQ and KOSPI listed pharmace...
Sales of listed pharmaceutical companies increased 11.5% in average, stating “We overcame the En Bloc Drug Price Reduction”
As sales of listed pharmaceutical companies increased 10% up last year, it is analyzed that they overcame hardships of the En Bloc Drug Price Reduction striking the pharmaceutical industry in 2012.
According to the Y...
Navipharm is rushing on patent challenges while Handok Teva had its debut
Competition to acquire the Priority Sale Item Approval Rights has been activated among generic pharmaceutical companies. The IP R&D company, Navipharm, has made sudden movements, facing the ‘Patent Linkage System’.
M...
The long expiration date of Tamiflu seems way too long
Tamiflu has been an issue due to its long expiration date compared to other pharmaceutical products. Vice president Chang-wook Choi of the Busan Pharmaceutical Association unveiled a picture of Tamiflu that has recent...
LG Life Sciences will target $500 million with its first domestic diabetes treatment ‘Zemiglo’LG Life Sciences will speed up on expanding its first domestic diabetes treatment ‘Zemiglo (generic name: gemigliptin)’ to global markets.
According to the company, Zemiglo, la...
|
Domestic pharmaceutical companies are catching up multinational ones in the KRW 600 billion domestic hyperlipidemia treatment market
In the hyperlipidemia treatment market, multinational and domestic pharmaceutical companies are having fierce competitions.
Last year, the size of the domestic hyperlipidemia treatment market was KRW 600 million (80%...
The largest cash dividends, KRW 3.2 billion, will be given to Dong-yeon Kim while Jang-han Lee and Il-sup Huh will receive KRW 2 billion and KRW 1.8 billion, respectively
Among owners of list pharmaceutical companies, president Dong-yeon Kim of Bukwang Pharm will receive the largest cash dividends from the 2014 settlement of accounts.
President Jang-han Lee of Chong Kun Dang and presi...
Will the era of domestic biosimilar successes open?
As the first biosimilar, the Sandoz’s ‘Zarxio (generic name: filgrastim)’, has recently acquired sale approvals in the U.S., biosimilars developed by domestic companies have attracted attention of the industry.
As a ...
While Mercilon is leading the contraceptive market, Bayer is having complex concerns
‘Mercilon’ is dominating in the pre-coital contraception pill market. Last year, it first exceeded KRW 10 billion sales to leave other pharmaceutical products behind.
Bayer Healthcare, planning to absorb the owning c...
Foreign direct investments of the domestic pharmaceutical industry in 2014 recorded the most ever
It is known that funds invested directly in foreign markets last year recorded the most ever in the history.
According to the ‘2014 Trend Analysis of Direct Investment to Foreign Markets by the Domestic Pharmaceutica...
